Bebtelovimab

Bebtelovimab is authorized for emergency use in the treatment of COVID-19. It is specifically intended for individuals with mild-to-moderate symptoms who are not hospitalized or requiring oxygen therapy or respiratory support. The monoclonal antibody aims to mitigate the severity of the disease caused by SARS-CoV-2.

Recommended Dosage: For adults (18 years and older) and pediatric patients (≥12 years, weighing at least 40 kg), the recommended dosage is 175 mg administered as a single intravenous injection over at least 30 seconds. Bebtelovimab should be administered as soon as possible after positive SARS-CoV-2 viral testing and within 7 days of symptom onset.

• Hypersensitivity and Infusion-Related Reactions: Significant allergic responses, including anaphylaxis, have been noted with comparable monoclonal antibodies. If there are noteworthy reactions, the administration of bebtelovimab should be halted, and appropriate supportive care should be initiated. Infusion-related reactions have the potential to manifest up to 24 hours post-injection and can be of a severe or life-threatening nature.
• Clinical Deterioration Following Administration: After undergoing bebtelovimab treatment, there is a possibility of exacerbation of COVID-19 symptoms. This deterioration may manifest as signs or symptoms such as fever, hypoxia, heightened respiratory difficulty, arrhythmia, fatigue, and changes in mental status. Some instances have necessitated hospitalization, and it remains unclear whether these events are linked to the use of the antibody or are a result of the natural progression of COVID-19.
• Limitations of Benefit and Potential Risks in Severe COVID-19: The effectiveness and potential risks of bebtelovimab in patients hospitalized due to COVID-19 have not been explored. Administering monoclonal antibodies, including bebtelovimab, to patients with severe COVID-19 requiring high-flow oxygen or mechanical ventilation may be associated with unfavorable clinical outcomes.

If you are considering the import of Bebtelovimab injections to India, please be aware that Bebtelovimab can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

Required Documentation for Import:

• A valid prescription from a qualified medical practitioner.
  
• Diagnostic reports of the patient.
  
• Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process: 

The order forBebtelovimab injections will be confirmed upon the receipt of the following documents:

• A valid prescription from a qualified doctor.
  
• An import permit, if applicable.

Availability of Bebtelovimab injections in India: 

Bebtelovimab injections is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Bebtelovimab injections can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Bebtelovimab injections

(prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

For inquiries regarding the price of Bebtelovimab injections in India and to initiate the ordering process, please reach out to us through the following contact details:

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Indian Pharma Network is proficient in sourcing Bebtelovimab injections from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient’s address, exclusively from New Delhi, India.

Can I use bebtelovimab if I have mild-to-moderate COVID-19 symptoms?

Yes, bebtelovimab is authorized for emergency use in individuals with mild-to-moderate symptoms who are not hospitalized or requiring oxygen therapy or respiratory support.

What is the recommended dosage of bebtelovimab?

The recommended dosage is 175 mg, administered as a single intravenous injection over at least 30 seconds.

When should bebtelovimab be administered after a positive COVID-19 test?

Bebtelovimab should be administered as soon as possible after positive SARS-CoV-2 viral testing and within 7 days of symptom onset.

Are there any contraindications to using bebtelovimab?

Based on available data, no contraindications have been identified for the emergency use of bebtelovimab.

What should I do if I experience a severe reaction during or after bebtelovimab infusion?

If clinically significant hypersensitivity reactions occur, discontinue bebtelovimab and seek appropriate supportive care. Infusion-related reactions may occur up to 24 hours post-injection.

Is bebtelovimab suitable for patients hospitalized due to severe COVID-19?

No, bebtelovimab has not been studied in patients hospitalized due to COVID-19 and may not be beneficial in those requiring high flow oxygen or mechanical ventilation, potentially leading to worse outcomes.